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Abstract
Background: The analysis of gene expression data shows that many genes display similarity in their expression profiles
suggesting some co-regulation. Here, we investigated the co-expression patterns in gene expression data and proposed a
correlation-based research method to stratify individuals.
Methodology/Principal Findings: Using blood from rheumatoid arthritis (RA) patients, we investigated the gene expression
profiles from whole blood using Affymetrix microarray technology. Co-expressed genes were analyzed by a biclustering
method, followed by gene ontology analysis of the relevant biclusters. Taking the type I interferon (IFN) pathway as an
example, a classification algorithm was developed from the 102 RA patients and extended to 10 systemic lupus
erythematosus (SLE) patients and 100 healthy volunteers to further characterize individuals. We developed a correlation-
based algorithm referred to as Classification Algorithm Based on a Biological Signature (CABS), an alternative to other
approaches focused specifically on the expression levels. This algorithm applied to the expression of 35 IFN-related genes
showed that the IFN signature presented a heterogeneous expression between RA, SLE and healthy controls which could
reflect the level of global IFN signature activation. Moreover, the monitoring of the IFN-related genes during the anti-TNF
treatment identified changes in type I IFN gene activity induced in RA patients.
Conclusions: In conclusion, we have proposed an original method to analyze genes sharing an expression pattern and a
biological function showing that the activation levels of a biological signature could be characterized by its overall state of
correlation.
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Introduction
A wide range of methods for microarray data analysis have
evolved, ranging from simple fold-change approaches to many
complex and computationally demanding techniques [1]. Gene
expression profiling by microarray technology has become a
widely used strategy for investigating the molecular mechanisms
underlying many complex diseases [2]. However, the analysis is
further complicated by the biological heterogeneity encountered in
most of the diseases.
A common observation in the analysis of gene expression is that
many genes show similar expression patterns [3] which may share
biological functions under common regulatory control. Moreover,
these co-expressed genes are frequently clustered according to
their expression patterns in subset of experimental conditions [4].
Thus, gene co-expression instead of differential expression could
be informative as well. Bi-clustering methods seek gene similarity
in subsets of available conditions, which is more appropriate for
functionally heterogeneous data [5,6].
We have further explored this approach to study the heteroge-
neity of rheumatoid arthritis (RA) patients regarding their mRNA
profiles in whole blood samples. In the context of RA, the clinical
presentation of patients shows a high degree of heterogeneity,
ranging from mild cases with a benign course to severe and erosive
disease. In RA, gene expression profiling has been used to stratify
patients based on molecular criteria using synovial tissue [7,8] and
more recently from peripheral blood cells [9].
Here, we took the signature of interferon (IFN)-related genes as
an example to study correlation levels between genes composing
that signature. A biclustering algorithm was applied to study a
large gene expression dataset from peripheral whole blood of 102
RA patients. A correlation-based search algorithm referred to as
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was developed to characterize patients based on their IFN
signature. In RA patients with an activated IFN signature, gene
expression levels were highly correlated and this was linked to the
level of global IFN signature activation.
Results
Analysis of heterogeneity in RA with the biclustering
method
Based on 102 RA patients, the study of biological data
heterogeneity was conducted with a biclustering approach. This
method using the SAMBA algorithm performs clustering on genes
and conditions simultaneously in order to identify subsets of genes
that show similar expression patterns across specific subsets of
patients and vice versa. After data filtering, 121 biclusters were
identified from 9,856 selected probe sets. To draw a clear picture
of these co-expressed gene groups, the TANGO algorithm was
used for GO functional enrichment analysis. The details of the
results are given in table S1. Among them, these results have
highlighted the importance of immune regulation across the
‘‘immune response’’ and ‘‘response to virus’’ ontology groups
(biclusters 4, 21, 34, 35 and 39; see Table S1 as supplement
information). Subsequently, we focused on bicluster 4 which
represents the largest number of genes in these two GO categories.
Ingenuity pathway analysis of IFN signature
To further elucidate the importance of immune regulation, we
conducted pathway analyses on bicluster 4 (n=37 genes). To
summarize, a pathway corresponding to interferon signaling
(IFI35, IFIT1, IFIT3, IFITM1, IRF9, MX1, OAS1, STAT2) was
prominently represented (B-H p-value=1.86E-13). Moreover, a
literature review showed that 35 genes among the 37 appeared
directly or indirectly related to interferon. Thereafter, IPA was
conducted on the 35 genes which composed the IFN signature.
IPA can not only build associations of genes identified in our
analysis (‘‘focus’’ genes), but also predict the involvement of
additional molecules not associated in the main gene list. Out of
the list, 32 genes were found in the IPA knowledge database, and
are labelled ‘‘focus genes’’. Based on these focus genes, IPA
generated a biological network (score 85, focus genes 32) providing
evidence that type I IFN represented by the IFNa and IFNb genes
is responsible for the activation of IFN-related genes (Figure 1).
The list of these 35 genes is presented in the right column of
figure 2.
Activation of IFN pathway in a sub-group of RA patients
To visualize the expression profiles of the 35 IFN-response
genes among all RA patients and to investigate their interactions, a
hierarchical clustering was performed with the Spotfire Decision
Site 8.2.1. This clustering separated the samples into two main
groups, one of patients with RA (n=26/102, 25.5%) with high
expression (Figure 2, blue dendrogram) of this set of IFN-related
genes (IFN
high) and another (n=76/102, 74.5%) with lower
expression (Figure 2, purple dendrogram) (IFN
low).
Characterization of the IFN signature based on a
correlation approach
The expression pattern of 35 IFN-response genes was defined
as the ‘‘IFN signature’’. To go further in the description of the
IFN-related genes, the correlation levels between the co-
expressed genes were assessed in the two groups of RA patients.
Interestingly, the analysis revealed disparities between correlation
levels. The group associated with high IFN expression level
showed a better correlation (Rmedian=0.63) than the other one
(Rmedian=0.33), with a significant difference (p=8.46E-13),
suggesting a functional difference in the activated state of these
genes. A classification algorithm was applied to obtain a better
characterization of the IFN signature based on the correlation of
the 35 gene expression levels. The results showed that the IFN
signature presented a large variation between individuals
(Figure 3). 15/100 HC (15%), 22/102 RA patients (22%) and
10/10 SLE patients (100%) with a decision variable $1 for the
high signature (IFN
high) were identified, while the remainder of
individuals, with a decision variable ,1, were defined as IFN
low.
From the sub-groups identified by the CABS, the comparison of
the correlation profiles showed heterogeneous distributions
(Figure 4). Two groups were observed, first with RA and SLE
patients with a high IFN signature and a median correlation of
0.63 and 0.68 respectively; second with RA patients and HC
IFN
low and a median correlation of 0.33 and 0.27 respectively.
However, the shape of the curve for the HC IFN
high
(Rmedian=0.44 ; Figure 4, blue line) is very different from that
seen for the IFN high RA or SLE patients and for the IFN low
RA or controls. This suggests a very heterogeneous activation
status of genes in this group of controls.
Comparison of characterization methods of IFN signature
A comparative analysis between correlation-based approach
(CABS) and the classical ‘‘IFN score’’ based on the average values
of gene expression was performed (Figure 5). First, this figure
showed a correlation between the decision variable (correlation
value) and the average values of gene expression (Spearman
correlation test, r=0.65, p-value,0.0001). Second, based on the
respective thresholds, this comparison revealed differences be-
tween both approaches (9%). Individuals (black triangles) with a
high average expression value of IFN-related genes were
associated with a low level of correlation and vice versa with
individuals represented by a black square.
Effect of TNF inhibition on IFN pathway activation
The functional relationship between TNF inhibition and
possible changes in IFN pathway activation was studied. CABS
was used to assess the correlation levels in RA patients before and
after anti-TNFa treatment. Out of the subgroup of 43 RA patients
treated with anti-TNF, 22 RA patients (11 RA IFN
high and 11 RA
IFN
low; infliximab n=6, etanercept n=10 and adalimumab n=6)
were evaluated at 6 months for treatment response using the
DAS28 criteria. Although the values appeared quite heteroge-
neous, a statistical significant decrease (p=0.0186) of the
correlation level was observed in patients associated with high
IFN signature (Figure 6A). In contrast, a statistical significant
increase (p=0.002) of correlation levels was seen in RA patients
with low IFN signature before treatment (Figure 6B). Despite a
significant increase, the majority of these RA patients IFN
low did
not reach the threshold of positivity. No statistical association was
observed between the molecular stratification of RA patients
(IFN
high/IFN
low) and the clinical characteristics presented in
table 1 or the response to treatment at 6 months.
Discussion
In this study, the heterogeneous nature of RA was addressed at
a molecular level and the data showed that disease characteristics
could be reflected by gene expression levels in whole blood. Using
microarray technology, RA patients could be categorized into 121
biclusters, sub-groups of patients sharing a same profile for a group
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a variation of the correlation level within 102 RA patients
representative to the RA population. Each patient can be
characterized by a single correlation value of the expression
observed for the 35 IFN-related genes. Interestingly, our results
revealed a heterogeneous IFN expression (Figure 2) characterized
by a correlation level of the gene expression which may reflect the
global IFN signature activation. This method allowed us to define
two well separated groups (IFN
low vs. IFN
high; p=8.46E-13) based
on the correlation levels with the IFN
high corresponding to 22% of
our RA patients cohort. In fact, it was shown that genes with
similar functions usually are co-expressed under certain experi-
mental conditions only [4]. The sample profiles can resemble to
the physiological relationships expected between the studied
samples [10]. Prieto C. et al. demonstrated that studies of
heterogeneous datasets, mixing many case samples from patho-
logical or altered states with ‘‘normal’’ samples disturb gene co-
expression analysis. In the context of these observations, our
results suggest that the co-expressed gene clusters, defining
functional groups, depend on the activation status.
The method commonly used in the literature does not take into
account the activation status of the biological signature, which
could generate some misclassification. Indeed, the increase of IFN
regulated genes has been reported in different diseases like SLE
[11], systemic sclerosis [12], multiple sclerosis [13] and in tissues
from patients with Sjo ¨gren’s syndrome [14], type I diabetes
[15,16] and dermatomyositis [17,18]. To characterize the IFN
signature, an IFN ‘‘score’’ is calculated for each patient and
control based on the average expression of genes which composed
the signature [9,11,15,18,19,20]. However, this approach does not
take into account the co-regulation of these IFN-related genes.
When genes are co-regulated under various biological conditions,
the corresponding expression profiles may display relative
similarity or co-expression [21]. Our method offers an alternative
with which the IFN signature could be characterized by the level
of global correlation (Figures 3 and 4) and not solely by the
Figure 1. The network derived from the 35 genes which composed the IFN signature using Ingenuity Pathway Analysis (IPA)
software. Edges (gene relationships) are displayed with labels that describe the nature of the relationship between nodes (genes). Nodes are
displayed using various shapes that represent the functional class of the gene product. Genes in red belong to the list of the 35 IFN-related genes.
Genes in blue were integrated into the computationally generated networks on the basis of the evidence stored in the IPA knowledge memory
indicating a relevance to this network. The network showed central connection represented by the type I interferon. The pink arrows represent the
direct and indirect interactions for genes of type I family of interferons (IFN-a, IFN-b).
doi:10.1371/journal.pone.0024828.g001
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expression of the IFN-related genes showed disparities in the
classification of HC and RA patients (9%, Figure 5). These
differences between gene expression and correlation levels in the
IFN signature could be explained by different factors. Studies
showed that IFN-related genes could be regulated by several
independent pathways on IFN signaling [22,23]. Their expression
could be also controlled by the polymorphic sequences which
mainly composed the promoter regions of theses genes [24,25].
These different factors could explain the presence of individual
heterogeneity in the expression of these genes and thus the
discrepancies observed between the two approaches.
To better understand differences between disease and healthy
status, different approaches like transcriptomics or proteomics
analyses allow the study of molecular networks and signaling
pathways, with the major challenge of integrating this information
into a systems approach [15]. Our method permits to identify truly
active biological networks associating only with high levels of
correlation of biological signature components. Indeed, taking into
account this new correlation aspect for the interpretation of
biological networks should allow capturing the actually activated
mechanisms at the cellular level.
Interestingly, such correlation-based approach can be advanta-
geously applied to investigate the dynamics of evolution of cellular
mechanisms like response to treatment. As an example, in the
context of RA, we have applied this method to monitor patients
treated by anti-TNF therapy. Although the cross-regulation of
TNFa and IFNa has been previously described [26], the effects of
anti-TNF treatment on the expression of IFN-related genes had
never been shown by such approach. The results showed that a
high IFN signature was conserved after anti-TNF treatment
(Figure 6A), while a significant increase was observed in RA
IFN
low six months after treatment (Figure 6B). However, the level
of positivity has never reached the one observed in SLE patients,
known to strongly express the IFN signature. This observation
could explain that RA patients treated with anti-TNF develop
rather benign clinical symptoms of SLE that are reversible after
discontinuation of therapy [27,28]. Contrary to a recent
Figure 2. Gene expression profiles from the IFN signature. Unsupervised hierarchical clustering of 35 IFN-related genes that distinguish
rheumatoid arthritis (RA) patients IFN
high (blue dendrogram) from RA patients IFN
low (purple dendrogram). Each row represents a gene; each column
shows the expression for 35 IFN-related genes expressed by each patients. Red indicates genes that are expressed at higher levels and green
indicates genes that are expressed at lower levels.
doi:10.1371/journal.pone.0024828.g002
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this IFN signature. The authors showed that an increased IFN-
response gene activity after anti-TNF treatment was linked to a
poor clinical outcome. In our results, only a trend was observed
according to the delta DAS28 score (p=0.07, data not shown).
Besides the difference in method used or the sample size which
may explain the discrepancies, our study presented RA patients
with a large panel of anti-TNF treatments (infliximab, etanercept
and adalimumab). Indeed, several studies suggest differential
effects of anti-TNF treatments on IFN-response activity which
could explain the lack of specificity in our study [29].
Interestingly, our method using CABS allowed us to pinpoint
type I IFN signaling as a means to stratify RA patients even
starting with whole blood transcriptomics analysis from samples
collected in PAXgene tubes. Similar analyses can be performed for
the other identified biclusters, highlighting the obvious advantage
of whole blood transcriptomics. Using the example of the IFN
signature, the use of correlations showed interest in the
characterization of the genes sharing both an expression pattern
and a biological function. The use of expression correlations may
be a better way to obtain a global picture of an activated signature
in various disease conditions.
Methods
Ethics statement
All subjects provided written informed consent and the study
was approved by the local Ethical Committee for clinical research
of the University hospitals of Lyon.
Patients and controls
102 RA patients fulfilling the revised American College of
Rheumatology 1987 criteria for RA [30] were enrolled. Their
clinical characteristics are shown in table 1. Among the 102 RA
patients, a subgroup of RA patients treated for 6 months with anti-
TNF, 22 RA patients characterized as IFN
high (n=11) and IFN
low
(n=11), were included (IFN
high group: infliximab n=4, etanercept
n=3 and adalimumab n=4; IFN
low group: infliximab n=2,
Figure 3. Stratification of individuals according to the IFN
signature. Each point represents a single individual with the decision
variable calculated from the Classification Algorithm based on a
Biological Signature (CABS). The shaded box indicates the normal
range according to the rule of the CABS: If Dhigh_low$1, the signature is
defined as ‘‘high signature’’ and If Dhigh_low,1, the signature is defined
as ‘‘low signature’’ knowing that Dhigh_low=CORhigh/CORlow.
doi:10.1371/journal.pone.0024828.g003
Figure 4. Correlation profiles from the different groups. A
correlation index was defined for each gene of the IFN signature as the
median of its correlations with the remaining genes. Thus, the
correlation profiles for the different groups: healthy controls (HC)
IFN
low (blue dotted), HC IFN
high (blue line), rheumatoid arthritis patients
(RA) IFN
low (red dotted) and RA IFN
high (red line) and systemic lupus
erythematosus patients (SLE) IFN
high (green line), are represented using
the 35 calculated correlation indexes from the IFN signature genes. The
median values of the correlation indexes obtained for the different
groups are 0.27, 0.44, 0.33, 0.63 and 0.68, respectively.
doi:10.1371/journal.pone.0024828.g004
Figure 5. Comparative analysis of characterization methods of
IFN signature. Each dot represents a single individual. The y-axis
represents the decision variable of the IFN signature calculated from
CABS. The grey dotted line indicates the threshold according to the rule
of the CABS: If Dhigh_low$1, the signature is defined as ‘‘high signature’’
and If Dhigh_low,1, the signature is defined as ‘‘low signature’’ knowing
that Dhigh_low=CORhigh/CORlow. The x-axis represents the average
values of gene expression of the IFN signature. The solid grey line
indicates the threshold of IFN response, by calculating the 95% limits of
the HC (normal values, defined as the mean (SD) expression of the 35
IFN-related genes, 61.96 SD). If the average gene expression is $9.68,
the signature is defined as ‘‘high signature’’ and if average gene
expression ratio is ,9.68, the signature is defined as ‘‘low signature’’.
The shaded boxes show the divergence observed between both
methods. The black triangles represent individuals with high average
values of gene expression and low decision variable. The black squares
represent individuals with low average values of gene expression and
high decision variable.
doi:10.1371/journal.pone.0024828.g005
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control group (IFN
high), 10 systemic lupus erythematosus patients
(SLE) fulfilling the American College of Rheumatology criteria for
the SLE [31] were studied. In addition, 100 age- and sex-matched
healthy control subjects (HC) without any familial history of RA,
autoimmune disease and concomitant medication were also
recruited.
Sample collection, processing and microarray
hybridization
Peripheral blood samples were collected in PAXgene
TM Blood
RNA tubes (PreAnalytix, Hilden, Germany) in order to stabilize
mRNA [32]. Blood samples were incubated at room temperature
for 2 h, and then stored at 220uC until RNA extraction according
to the manufacturer’s instructions. Briefly, RNA was isolated using
the PAXgene
TM Blood RNA kit (PreAnalytix). Following cell lysis,
nucleic acids were pelleted and treated with a buffer containing
proteinase K. After digestion with a RNase-free DNase (Qiagen,
Valencia, CA, USA), RNA was subsequently purified on PAXgen-
e
TM spin columns and eluted in 80 ml of elution buffer. The quality
of RNA was determined with the BioanalyzerH 2100 (Agilent
Technologies, Waldbronn, Germany), following the manufacturer’s
protocol. cDNA was synthesized from 50 ng of total RNA using the
WT-Ovation
TM System (NuGEN, San Carlos, CA, USA) powered
by Ribo-SPIA
TM technology. Fragmented cDNA was end labeled
with a biotin-conjugated nucleotide analog (DLR-1a; Affymetrix,
Santa Clara, CA, USA) using terminal transferase (Roche
Diagnostics, Mannheim, Germany). Fragmented and labeled
cDNA was hybridized for 18 h at 50uC in a hybridization solution
containing 7% DMSO. Hybridization was performed using
GeneChipH Human Genome U133 Plus 2.0 arrays (Affymetrix),
containing 54,675 probe sets corresponding to 38,500 identified
genes. After washing, chips were stained with streptavidin-
phycoerythrin according to Affymetrix EukGE-WS2v4 protocol
using the Fluidic FS450 station. The microarrayswerereadwith the
GeneChipH Scanner 3000 (Affymetrix). Affymetrix GeneChip
Operating Software version 1.4 (GCOS) was used to manage
Affymetrix GeneChip array data and to automate the control of
GeneChip fluidics stations and scanners.
Data analysis
Data processing. Expression data were generated using the
Robust Multi-array Average (RMA) method [33] implemented in
the Affy package of the Bioconductor microarray analysis
environment (http://www.bioconductor.org). The RMA method
consists of three steps: background adjustment, quantile normal-
ization [34] and probe set summary of the log-normalized data
applying a median polishing procedure. Before the analysis of
heterogeneity, two filters were applied based on expression level
and variability to lower the dimensionality of the data and to avoid
false discoveries. First, genes with a median expression value below
a given threshold were eliminated. This threshold was set to 6 in
log base 2 corresponding to twice the average background level.
The second filter eliminated genes with a low variation. Thus, the
Median Absolute Deviation (MAD) for the remaining genes was
calculated and those with a MAD lower than the median of the
MAD calculated over the remaining genes after intensity based
filtering were eliminated.
Biclustering and functional enrichment analyses. The
SAMBA algorithm (Statistical-Algorithmic Method for Bicluster
Figure 6. Follow-up the IFN signature in patients with rheumatoid arthritis (RA) treated with anti-TNF. Each point represents a single
individual with the decision variable calculated from the Classification Algorithm based on a Biological Signature (CABS). The shaded box indicates
the normal range according to the rule of the CABS: If Dhigh_low$1, the signature is defined as ‘‘high signature’’ and If Dhigh_low,1, the signature is
defined as ‘‘low signature’’ knowing that Dhigh_low=CORhigh/CORlow. The Wilcoxon signed rank test was used to evaluate the statistical significance
between patients before and after anti-TNF treatment A)( * p=0.0186) B) (**p=0.002).
doi:10.1371/journal.pone.0024828.g006
Table 1. Demographic and clinical characteristics of the
patients and control subjects.
RA
(n=102)
SLE
(n=10)
C
(n=100)
Demographic data
Age
a 50 (40,3–60) 37 (34–44) 57 (52–63)
Sex: Female, Male 79F, 23M 10F 86F, 14M
Disease characteristics
ESR
a 18 (8–44) NA NA
Rheumatoid Factor pos.(%) 70 (68,6) NA NA
Disease duration (years)
a 5 (2–9) 4 (3–6) NA
Disease activity 4,2 (3,3–5,2)
b 13 (12–17.5)
c NA
Medication
MTX (%) 87 (85,3) NA NA
MTX dose
a 15 (15–20) NA NA
aMedian (Q1–Q3).
bDAS28: Disease Activity Score.
cSLEDAI: Systemic Lupus Erythematosus Disease Activity Index.
ESR: Erythrocyte Sedimentation Rate; MTX: Methotrexate.
doi:10.1371/journal.pone.0024828.t001
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ANalyzer and DisplayER) was used for the biclustering [35].
This algorithm uses probabilistic modeling of the data and
theoretical graph techniques to identify such subsets of genes that
behave similarly across a subset of patients [36].
The TANGO algorithm (Tool for Analysis of GO enrichment),
implemented in EXPANDER 4.0.3, was used to identify the
biological significance of these biclusters [35].
Interferon molecular pathway analysis. Canonical
pathway analyses was performed to define overrepresentation of
canonical pathways of the selected genes. Canonical pathway
analyses of specific genes coming from statistical analysis were
performed using Ingenuity Pathway Analysis (IPA), (www.
ingenuity.com). B-H multiple testing correction p-value test was
used to calculate the p-value for determining the probability that
each canonical pathway assigned to the dataset was due to chance
alone. P-value,0.01 was applied in calculations and the Human
Genome U133 Plus 2.0 array was used as the reference when
ranking the statistical significance of canonical pathways.
Networks of the IFN genes were constructed using Ingenuity
Pathway Analysis (IPA), (www.ingenuity.com). Genes were found
in the IPA knowledge database are labeled ‘‘focus’’ genes. Based
on the focus genes, IPA generated a set of molecular networks with
a cutoff of 70 genes for each network based on interactions
between uploaded genes and all other genes/proteins stored in the
knowledge base. Each network is assigned a score according to the
number of focus genes in our dataset. These scores are derived
from negative logarithm of the P and are indicators of the degree
of significance. Scores of 4 or higher have 99.9% confidence level
of significance as defined in detail elsewhere [37].
Classification Algorithm based on a Biological Signature
(CABS). Taking the example of the IFN-related genes, a
classification algorithm was developed to identify individuals
with or without this biological signature. Applied to the IFN-
related genes, the CABS is divided into three steps.
Step 1 Prototype construction: Two groups of RA patients (IFN
high;
IFN
low) were identified from the hierarchical clustering represent-
ing the 35 IFN-related genes which characterized the IFN
signature (Figure 2). The prototype was defined from these two
groups. Median expression values was calculated in the two
groups. Prototype Pi was defined from group i; the vector
(Gi1,…,GiM) represents the expression of the prototype Pi, where
i is high or low, Gij is the median expression of gene j in group i, M
is the size of the IFN signature.
Step 2 Decision Variable Calculation: Given the definition of the
prototypes described above, a criteria was needed to assess the
similarity of a given individual to those prototypes. For a given
individual, the IFN signature profile was defined as the vector
corresponding to the expression level of the 35 genes constituting
the signature. The similarity of this profile with both prototypes
was calculated using the Pearson correlation coefficient and noted
CORhigh et CORlow. The decision variable calculation was given by
the ratio between these two correlations: Dhigh_low=CORhigh/CORlow
indicating proximity to one or other of the prototypes.
Step 3 : Decision Making: Given the decision variable describe
above, an individual was assigned High IFN if the ratio Dhigh_low$1
meaning that CORhigh$CORlow. Inversely, an individual was
assigned low IFN if the ratio Dhigh_low,1 meaning that CORhigh,
CORlow.
Supporting Information
Table S1 Ontological analysis of the 121 biclusters
obtained from the 102 RA patients. The TANGO algorithm
(Tool for Analysis of GO enrichment) was used to identify the
biological significance of 121 biclusters from 9,856 selected probe
sets (see material and methods for details). Among them, these
results have highlighted the importance of immune regulation
across the ‘‘immune response’’ and ‘‘response to virus’’ ontology
groups (biclusters 4, 21, 34, 35 and 39. Processes with corrected p
value,0.05 were considered significant [36].
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